NEW DELHI, September 25: Investment by companies selected under the Production Linked Incentive Scheme for Pharmaceuticals reached ₹46,744 crore by June 2026, significantly exceeding the targeted investment of ₹17,275 crore, according to the Department of Pharmaceuticals.
The Pharmaceuticals PLI scheme, approved with a financial outlay of ₹15,000 crore, has selected 55 applicants, including 20 MSMEs. The ₹46,744 crore figure represents investment made by beneficiary companies under the scheme and is separate from the government’s scheme outlay.
Cumulative sales by participating companies reached ₹4,02,869 crore from the start of the performance period in FY 2022-23 through June 2026. Of this, exports accounted for ₹2,57,370 crore. The government said the scheme had generated 1,21,294 jobs by June.
The programme supports manufacturing across a range of pharmaceutical products, including biopharmaceuticals, complex generics, patented and off-patent drugs, orphan drugs, auto-immune medicines and specified active pharmaceutical ingredients, drug intermediates and key starting materials.
The government also reported progress under the separate PLI Scheme for Bulk Drugs. The ₹6,940 crore scheme has approved 48 projects, with actual investment reaching ₹5,210.74 crore against committed investment of ₹4,330 crore.
Of these, 39 projects covering 28 APIs and key starting materials had been commissioned by June 2026. Beneficiaries recorded sales of ₹3,792.49 crore, including exports worth ₹560.16 crore, while employment under the scheme stood at around 5,127.
The government said the scheme has supported domestic production of fermentation-based products including Penicillin-G, Clavulanic Acid and Rifampicin.
Under the PLI Scheme for Promoting Domestic Manufacturing of Medical Devices, which has an outlay of ₹3,420 crore, production has commenced for 57 unique medical devices.
These include MRI machines, CT scanners, Cath Labs, linear accelerators, C-Arms, mammography machines, ultrasound systems, anaesthesia machines and heart valves.
The government said companies including GE Healthcare, Siemens, Philips, Varex, Nipro and Omron have established or expanded manufacturing operations in India under the medical devices programme.
The three schemes separately target finished pharmaceuticals, critical bulk drugs and medical devices as part of the government’s broader effort to expand domestic manufacturing capacity and reduce dependence on imports.
Read also: Fujifilm to invest ₹800 crore in India semiconductor-materials plant; production targeted in FY2028
